Nelson Michael
#50,356
Most Influential Person Now
American infectious disease physician
Nelson Michael's AcademicInfluence.com Rankings
Nelson Michaelbiology Degrees
Biology
#4839
World Rank
#7166
Historical Rank
Virology
#213
World Rank
#220
Historical Rank
Immunology
#455
World Rank
#472
Historical Rank
Nelson Michaelphilosophy Degrees
Philosophy
#6870
World Rank
#9981
Historical Rank
Logic
#3965
World Rank
#5202
Historical Rank
Download Badge
Biology Philosophy
Nelson Michael's Degrees
- Doctorate Medicine Harvard University
Why Is Nelson Michael Influential?
(Suggest an Edit or Addition)According to Wikipedia, Nelson L. Michael is an American infectious disease researcher. He has served for nearly 30 years in the United States Army and been directly involved with significant advancements in understanding the pathology of and vaccine development for diseases like HIV, Zika, Ebola and more. Much of his career has been spent at the Walter Reed Army Institute of Research.
Nelson Michael's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Joint United Nations Programme on HIV/AIDS. (2004) (3399)
- Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. (2009) (3011)
- Immune-correlates analysis of an HIV-1 vaccine efficacy trial. (2012) (1506)
- Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys (2014) (507)
- The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression (1997) (505)
- Genetic acceleration of AIDS progression by a promoter variant of CCR5. (1998) (483)
- Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys (2011) (481)
- Vaccine Protection Against Zika Virus from Brazil (2016) (464)
- Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys (2016) (445)
- Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env-V2 (2012) (431)
- Central nervous system viral invasion and inflammation during acute HIV infection. (2012) (426)
- Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination (2014) (402)
- Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. (2013) (381)
- Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family (2012) (374)
- Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines (2014) (349)
- Influence of HLA-C Expression Level on HIV Control (2013) (343)
- A Recombinant Vesicular Stomatitis Virus Ebola Vaccine (2017) (333)
- Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG (2013) (328)
- Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys (2013) (312)
- Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection (2012) (288)
- Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology (2015) (286)
- Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials (2012) (283)
- Effects of CCR5- 32, CCR2-64I, and SDF-1 3A Alleles on HIV-1 Disease Progression: An International Meta-Analysis of Individual-Patient Data (2001) (282)
- The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression (1997) (267)
- HIV-1 infection in a man homozygous for CCR5▵32 (1997) (258)
- International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. (2011) (257)
- Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection (2014) (253)
- Genetic impact of vaccination on breakthrough HIV-1 sequences from the Step trial (2011) (229)
- Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial (2013) (226)
- Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation (2014) (223)
- Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys (2016) (222)
- Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) (2018) (214)
- Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. (2016) (212)
- Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection (2018) (211)
- COMPASS identifies T-cell subsets correlated with clinical outcomes (2015) (207)
- Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial (2019) (202)
- The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. (2012) (200)
- Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. (2012) (199)
- Exclusive and Persistent Use of the Entry Coreceptor CXCR4 by Human Immunodeficiency Virus Type 1 from a Subject Homozygous for CCR5 Δ32 (1998) (196)
- Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda (2000) (190)
- HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART☆☆☆ (2016) (183)
- Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition (2016) (182)
- A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants (2020) (182)
- Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. (2015) (182)
- Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection (2017) (176)
- Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. (1995) (174)
- Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial (2013) (173)
- Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease (1992) (170)
- Cross-Clade Ultrasensitive PCR-Based Assays To Measure HIV Persistence in Large-Cohort Studies (2014) (167)
- Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. (2015) (167)
- HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities (2014) (167)
- Host determinants of HIV-1 control in African Americans. (2010) (165)
- Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. (2008) (165)
- Evaluation of Performance of the Gen-Probe Human Immunodeficiency Virus Type 1 Viral Load Assay Using Primary Subtype A, C, and D Isolates from Kenya (2000) (150)
- Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials (2017) (148)
- HIV-1 entry inhibitors: Evading the issue (1999) (143)
- Reference Ranges for the Clinical Laboratory Derived from a Rural Population in Kericho, Kenya (2008) (139)
- Development of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 and Performance of an Improved AMPLICOR HIV-1 MONITOR Test with Isolates of Diverse Subtypes (1999) (138)
- The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope (2012) (133)
- Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. (2001) (133)
- Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques (2015) (133)
- Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. (2008) (132)
- Genomic Organization and Functional Characterization of the Chemokine Receptor CXCR4, a Major Entry Co-receptor for Human Immunodeficiency Virus Type 1* (1998) (132)
- Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIVmac251 Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial (2012) (132)
- Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. (1995) (131)
- A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 (2002) (127)
- Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus (1995) (122)
- Host genetic influences on HIV-1 pathogenesis. (1999) (122)
- Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques (2017) (121)
- Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. (2019) (120)
- Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells (2018) (119)
- A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). (2010) (118)
- Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge (2017) (111)
- Change in Brain Magnetic Resonance Spectroscopy after Treatment during Acute HIV Infection (2012) (107)
- Performance of the OraQuick Rapid Antibody Test for Diagnosis of Human Immunodeficiency Virus Type 1 Infection in Patients with Various Levels of Exposure to Highly Active Antiretroviral Therapy (2003) (106)
- Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation (2002) (104)
- Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. (2008) (104)
- Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial (2015) (103)
- Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection (2003) (102)
- Durability and correlates of vaccine protection against Zika virus in rhesus monkeys (2017) (102)
- Performance of the Affymetrix GeneChip HIV PRT 440 Platform for Antiretroviral Drug Resistance Genotyping of Human Immunodeficiency Virus Type 1 Clades and Viral Isolates with Length Polymorphisms (1999) (100)
- FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. (2014) (99)
- Circulating HIV-Specific Interleukin-21(+)CD4(+) T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions. (2016) (96)
- HIV-1 Infection in Individuals With the CCR5-Δ32/Δ32 Genotype: Acquisition of Syncytium-Inducing Virus at Seroconversion (2002) (94)
- Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion (2012) (93)
- A novel acute HIV infection staging system based on 4th generation immunoassay (2013) (93)
- Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology. (2016) (93)
- Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. (1997) (93)
- Neutralizing Monoclonal Antibodies Block Human Immunodeficiency Virus Type 1 Infection of Dendritic Cells and Transmission to T Cells (1998) (93)
- Immunologic and virologic events in early HIV infection predict subsequent rate of progression. (2010) (92)
- Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns (1991) (91)
- Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort (1995) (88)
- Reference Intervals in Healthy Adult Ugandan Blood Donors and Their Impact on Conducting International Vaccine Trials (2008) (88)
- Negative-strand RNA transcripts are produced in human immunodeficiency virus type 1-infected cells and patients by a novel promoter downregulated by Tat (1994) (86)
- Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate (2010) (85)
- Prospects for a Zika Virus Vaccine (2017) (83)
- Naturally occurring genotypes of the human immunodeficiency virus type 1 long terminal repeat display a wide range of basal and Tat-induced transcriptional activities (1994) (83)
- Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. (2009) (79)
- Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection--evidence for highly susceptible human hosts. (1997) (79)
- Determinations of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma: Reassessment of Parameters Affecting Assay Outcome (1998) (78)
- Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes (2009) (78)
- Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection (2017) (77)
- CCR2-64I Polymorphism Is Not Associated with Altered CCR5 Expression or Coreceptor Function (1999) (77)
- Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. (2004) (76)
- HIV-1 infection in a man homozygous for CCR5 delta 32. (1997) (75)
- Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial (2018) (74)
- Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia (2015) (73)
- Shorter survival of SDF1-3'A/3'A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection. (2000) (72)
- Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection (2015) (70)
- Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1 (2010) (69)
- Human immunodeficiency virus vaccine trials. (2012) (69)
- Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection (2016) (68)
- Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models. (2020) (68)
- CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome (2019) (67)
- Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression (1995) (67)
- Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees (2013) (67)
- The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC in Rhesus Monkeys (2013) (66)
- Identification of CRF34_01B, a second circulating recombinant form unrelated to and more complex than CRF15_01B, among injecting drug users in northern Thailand. (2007) (65)
- Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. (2013) (63)
- Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs (2015) (62)
- Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. (1998) (61)
- Use of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 To Assess the Performance of Viral RNA Quantitation Tests (2000) (60)
- Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. (2009) (60)
- Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function (1997) (59)
- High-throughput multiplex HLA genotyping by next-generation sequencing using multi-locus individual tagging (2014) (57)
- CCL3L1 and HIV/AIDS susceptibility (2009) (57)
- Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. (2014) (57)
- Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification (2015) (56)
- Effect of HIV infection and antiretroviral therapy on immune cellular functions. (2019) (56)
- HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. (2002) (56)
- Impact of viral infection on the gene expression profiles of proliferating normal human peripheral blood mononuclear cells infected with HIV type 1 RF. (2002) (55)
- Elevated Natural Killer Cell Activity Despite Altered Functional and Phenotypic Profile in Ugandans With HIV-1 Clade A or Clade D Infection (2009) (55)
- Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. (2008) (54)
- V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144 (2017) (53)
- Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand (2011) (53)
- Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. (2014) (53)
- A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates (2021) (53)
- Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy (2018) (50)
- Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. (2019) (50)
- A nascent HIV type 1 epidemic among injecting drug users in Kabul, Afghanistan is dominated by complex AD recombinant strain, CRF35_AD. (2007) (50)
- Assessment of the Kinetics of Treponema pallidum Dissemination into Blood and Tissues in Experimental Syphilis by Real-Time Quantitative PCR (2007) (49)
- Longitudinal Analysis Reveals Early Development of Three MPER‐Directed Neutralizing Antibody Lineages from an HIV‐1‐Infected Individual (2019) (49)
- Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses (2014) (49)
- Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial (2017) (48)
- Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection (2020) (48)
- CCR5-Δ32 gene deletion in HIV-1 infected patients (1997) (47)
- Gag-Specific Cellular Immunity Determines In Vitro Viral Inhibition and In Vivo Virologic Control following Simian Immunodeficiency Virus Challenges of Vaccinated Rhesus Monkeys (2012) (47)
- Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection (2017) (47)
- Performance Characteristics of Human Immunodeficiency Virus Type 1 (HIV-1) Genotyping Systems in Sequence-Based Analysis of Subtypes Other than HIV-1 Subtype B (2003) (47)
- Natural history of human immunodeficiency virus infection. (1991) (47)
- Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial (2015) (45)
- Innate and Adaptive Immune Responses Both Contribute to Pathological CD4 T Cell Activation in HIV-1 Infected Ugandans (2011) (45)
- Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals (2014) (45)
- Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120 (2017) (45)
- The Protective Effect of Circumcision on HIV Incidence in Rural Low-Risk Men Circumcised Predominantly by Traditional Circumcisers in Kenya: Two-Year Follow-Up of the Kericho HIV Cohort Study (2007) (45)
- HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition (2015) (45)
- Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens (2012) (45)
- SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity (2021) (44)
- Comparative Analysis of HIV‐1 Viral Load Assays on Subtype Quantification: Bayer Versant HIV‐1 RNA 3.0 Versus Roche Amplicor HIV‐1 Monitor Version 1.5 (2002) (44)
- Relatively Low HIV Infection Rates in Rural Uganda, but with High Potential for a Rise: A Cohort Study in Kayunga District, Uganda (2009) (43)
- The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. (2009) (43)
- Noninfectious Comorbidity in the African Cohort Study (AFRICOS). (2018) (43)
- TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1 (2015) (42)
- HLA class I allele and haplotype diversity in Ugandans supports the presence of a major east African genetic cluster. (2009) (42)
- HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders (2015) (40)
- Class I HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania. (2010) (40)
- Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor (2020) (40)
- A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein (2020) (39)
- SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity (2021) (39)
- Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. (2019) (39)
- Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa (2019) (38)
- Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor (2015) (38)
- All eight unassigned reading frames of mouse mitochondrial DNA are expressed. (1984) (38)
- A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge (2021) (37)
- Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees (2015) (37)
- Contraceptive Use in Women Enrolled into Preventive HIV Vaccine Trials: Experience from a Phase I/II Trial in East Africa (2009) (37)
- Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment (2021) (36)
- Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination (2018) (36)
- Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation (2016) (36)
- Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial (2017) (35)
- Large-Scale Human Immunodeficiency Virus Rapid Test Evaluation in a Low-Prevalence Ugandan Blood Bank Population (2007) (35)
- Killer cell immunoglobulin–like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1 (2018) (35)
- Evaluation of HIV type 1 strains in men having sex with men and in female sex workers in Mombasa, Kenya. (2010) (35)
- Detection of HIV-1 Neutralizing Antibodies in a Human CD4+/CXCR4+/CCR5+ T-Lymphoblastoid Cell Assay System (2013) (34)
- HLA tapasin independence: broader peptide repertoire and HIV control (2020) (34)
- Lost in translation: implications of HIV-1 codon usage for immune escape and drug resistance. (2004) (34)
- Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption (2020) (34)
- Viral phenotype and CCR5 genotype (1999) (33)
- Risk Factors for HIV-1 Infection in a Longitudinal, Prospective Cohort of Adults From the Mbeya Region, Tanzania (2011) (33)
- Knowledge, attitudes, and beliefs about HIV pre-exposure prophylaxis among US Air Force Health Care Providers (2016) (33)
- Individual and Sexual Network Predictors of HIV Incidence Among Men Who Have Sex With Men in Nigeria (2019) (32)
- Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant (2017) (32)
- Oral preexposure prophylaxis for HIV--another arrow in the quiver? (2010) (32)
- Laboratory evaluation of rapid test kits to detect hepatitis C antibody for use in predonation screening in emergency settings (2013) (32)
- Cryptic Determinant of α4β7 Binding in the V2 Loop of HIV-1 gp120 (2014) (31)
- HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis (2018) (31)
- Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques (2021) (30)
- HIV-1 proviral genotypes from the peripheral blood mononuclear cells of an infected patient are differentially represented in expressed sequences. (1993) (30)
- Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection (2017) (30)
- Molecular Evolution of the HIV-1 Thai Epidemic between the Time of RV144 Immunogen Selection to the Execution of the Vaccine Efficacy Trial (2013) (29)
- Major histocompatibility complex genotype is associated with disease progression and virus load levels in a cohort of human immunodeficiency virus type 1-infected Caucasians and African Americans. (1998) (29)
- Comparative Analysis of HIV-1 Viral Load Assays on Subtype Quantification: Bayer Versant HIV-1 RNA 3.0 Versus Roche Amplicor HIV-1 Monitor Version 1.5 (2002) (29)
- Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection (2020) (29)
- Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection (2016) (29)
- Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge (2020) (29)
- High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection (2017) (29)
- First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector (2018) (29)
- Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers (2017) (29)
- Viral and Host Factors Associated With the HIV-1 Viral Load Setpoint in Adults From Mbeya Region, Tanzania (2010) (28)
- Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection (2018) (28)
- Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations (2021) (27)
- HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development. (2013) (27)
- Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates (2021) (27)
- Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research (2015) (27)
- Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size. (2018) (27)
- Aggregate complexes of HIV-1 induced by multimeric antibodies (2014) (27)
- Use of Rapid and Conventional Testing Technologies for Human Immunodeficiency Virus Type 1 Serologic Screening in a Rural Kenyan Reference Laboratory (2004) (26)
- CXCR4 polymorphisms and HIV-1 pathogenesis. (1998) (26)
- Predominance of defective proviral sequences in an HIV + long-term non-progressor. (1996) (26)
- Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques (2018) (26)
- Prevalence of resistance mutations in HIV-1-Infected Hondurans at the beginning of the National Antiretroviral Therapy Program. (2008) (26)
- Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. (2007) (26)
- Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection (2016) (25)
- Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16–STING–Type I IFN Pathway and AIM2 Sensor (2017) (25)
- Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. (2001) (24)
- Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. (2020) (24)
- Altered Memory Circulating T Follicular Helper-B Cell Interaction in Early Acute HIV Infection (2016) (24)
- The Role of Natural Killer (NK) Cells and NK Cell Receptor Polymorphisms in the Assessment of HIV-1 Neutralization (2012) (24)
- Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments (2018) (24)
- Use of Stored Serum from Uganda for Development and Evaluation of a Human Immunodeficiency Virus Type 1 Testing Algorithm Involving Multiple Rapid Immunoassays (2005) (24)
- HIV‐specific antibody‐dependent phagocytosis matures during HIV infection (2014) (24)
- Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine (2019) (24)
- High‐throughput next‐generation sequencing to genotype six classical HLA loci from 96 donors in a single MiSeq run (2017) (24)
- SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses (2021) (23)
- Sexually transmitted infections and sexual behaviour of deploying shipboard US military personnel: a cross-sectional analysis (2015) (23)
- Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. (2020) (23)
- Sensitivity of the Multispot HIV-1/HIV-2 Rapid Test Using Samples from Human Immunodeficiency Virus Type 1-Positive Individuals with Various Levels of Exposure to Highly Active Antiretroviral Therapy (2006) (23)
- Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study (2022) (23)
- High-throughput genotyping of KIR2DL2/L3, KIR3DL1/S1, and their HLA class I ligands using real-time PCR. (2009) (22)
- Cell Type-Specific Proteasomal Processing of HIV-1 Gag-p24 Results in an Altered Epitope Repertoire (2010) (22)
- Lessons from HIV-1 vaccine efficacy trials (2016) (22)
- Quality Monitoring of HIV-1-Infected and Uninfected Peripheral Blood Mononuclear Cell Samples in a Resource-Limited Setting (2010) (22)
- Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost (2017) (22)
- A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials (2019) (22)
- Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities (2018) (21)
- A SARS-CoV-2 vaccine candidate would likely match all currently circulating strains (2020) (21)
- Clinical implications of identifying non-B subtypes of human immunodeficiency virus type 1 infection. (2000) (21)
- Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques (2021) (21)
- Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric conformation as vaccine antigen. (2019) (21)
- Construction and biological characterization of infectious molecular clones of HIV-1 subtypes B and E (CRF01_AE) generated by the polymerase chain reaction. (2000) (20)
- HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels. (2015) (20)
- Comparison of serum and plasma viral RNA measurements in primary and chronic human immunodeficiency virus type 1 infection. (1997) (20)
- Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences (2016) (20)
- Effect of cytokines on Siglec-1 and HIV-1 entry in monocyte–derived macrophages: the importance of HIV-1 envelope V1V2 region (2015) (19)
- Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide (2014) (19)
- HIV-1 Incidence Rates and Risk Factors in Agricultural Workers and Dependents in Rural Kenya: 36-Month Follow-Up of the Kericho HIV Cohort Study (2010) (19)
- Designing the epitope flanking regions for optimal generation of CTL epitopes. (2014) (19)
- Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7R− Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity (2019) (19)
- Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand (2020) (19)
- Immunology of protection from Ebola virus infection (2015) (19)
- Antibodies induced by liposomal protein exhibit dual binding to protein and lipid epitopes. (2008) (19)
- Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens (2017) (18)
- Human Immunodeficiency Virus Type 1 Infection Is Associated with Increased NK Cell Polyfunctionality and Higher Levels of KIR3DL1+ NK Cells in Ugandans Carrying the HLA-B Bw4 Motif (2010) (18)
- HIV-1 Envelope Resistance to Proteasomal Cleavage: Implications for Vaccine Induced Immune Responses (2012) (18)
- Rare serotype adenoviral vectors for HIV vaccine development. (2012) (18)
- Sequences and phylogenetic analysis of the nef gene from Thai subjects harboring subtype E HIV-1. (1996) (18)
- Ethics Preparedness for Public Health Emergencies: Recommendations From the Presidential Bioethics Commission (2015) (18)
- Distinct circulating recombinant HIV-1 strains among injecting drug users and sex workers in Afghanistan. (2010) (18)
- Pilot studies for development of an HIV subtype panel for surveillance of global diversity. (2012) (18)
- Transfusion‐transmitted human T‐lymphotropic virus Type I infection in a United States military emergency whole blood transfusion recipient in Afghanistan, 2010 (2013) (17)
- Dynamics of cell-free viral burden in HIV-1-infected patients. (1997) (17)
- Accelerating HIV-1 Vaccine Efficacy Trials (2014) (17)
- Impaired natural killer cell responses are associated with loss of the highly activated NKG2A+CD57+CD56dim subset in HIV-1 subtype D infection in Uganda (2014) (17)
- Chikungunya and O’nyong-nyong Viruses in Uganda: Implications for Diagnostics (2019) (17)
- TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption (2021) (17)
- Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant (2018) (17)
- Chlamydia trachomatis infection rates among a cohort of mobile soldiers stationed at Fort Bragg, North Carolina, 2005–2010 (2014) (16)
- Time to change the paradigm: limited condom and lubricant use among Nigerian men who have sex with men and transgender women despite availability and counseling. (2019) (16)
- Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. (2020) (16)
- Epidemiology of HIV among US Air Force Military Personnel, 1996–2011 (2015) (16)
- The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes (2019) (16)
- Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee☆ (2015) (16)
- Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation (2020) (15)
- HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. (2020) (15)
- Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency (2019) (15)
- Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection (2017) (15)
- HIV infection among U.S. Army and Air Force military personnel: sociodemographic and genotyping analysis. (2010) (15)
- Natural killer cell-mediated innate sieve effect on HIV-1: the impact of KIR/HLA polymorphism on HIV-1 subtype-specific acquisition in east Africa. (2013) (15)
- Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans (2020) (15)
- Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women (2017) (15)
- Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 Infection (2019) (14)
- Evaluation of Performance of Two Rapid Tests for Detection of HIV-1 and -2 in High- and Low-Prevalence Populations in Nigeria (2015) (14)
- Viral kinetics in untreated versus treated acute HIV infection in prospective cohort studies in Thailand (2017) (14)
- CCR2-64I polymorphism, syncytium-inducing human immunodeficiency virus strains, and disease progression. (2000) (14)
- Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound (2020) (14)
- A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity. (2018) (14)
- Anogenital HIV RNA in Thai men who have sex with men in Bangkok during acute HIV infection and after randomization to standard vs. intensified antiretroviral regimens (2015) (14)
- HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial (2014) (14)
- Transcription regulation of human chemokine receptor CCR3: evidence for a rare TATA-less promoter structure conserved between drosophila and humans. (2002) (14)
- B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. (2021) (13)
- Expression of the Mouse Mitochondrial DNA Genome (1982) (13)
- Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. (2016) (13)
- Full-length next-generation sequencing of HLA class I and II genes in a cohort from Thailand. (2018) (13)
- Medical Encounter Characteristics of HIV Seroconverters in the US Army and Air Force, 2000–2004 (2011) (13)
- Identification of Acute HIV-1 Infection by Hologic Aptima HIV-1 RNA Qualitative Assay (2017) (13)
- HIV Preexposure Prophylaxis in the U.S. Military Services — 2014–2016 (2018) (13)
- Short communication: Investigation of incident HIV infections among U.S. army soldiers deployed to Afghanistan and Iraq, 2001-2007. (2012) (13)
- Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection (2015) (12)
- Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling. (2013) (12)
- HIV PrEP in the Military: Experience at a Tertiary Care Military Medical Center. (2018) (12)
- RecDraw: a software package for the representation of HIV-1 recombinant structures. (2010) (12)
- Human Primary Macrophages Derived In Vitro from Circulating Monocytes Comprise Adherent and Non-Adherent Subsets with Differential Expression of Siglec-1 and CD4 and Permissiveness to HIV-1 Infection (2017) (12)
- Significant contribution of subtype G to HIV-1 genetic complexity in Nigeria identified by a newly developed subtyping assay specific for subtype G and CRF02_AG (2016) (12)
- Brief Report: Differential Associations of Interleukin 6 and Intestinal Fatty Acid-Binding Protein With Progressive Untreated HIV-1 Infection in Rakai, Uganda (2016) (12)
- Molecular epidemiology of a primarily MSM acute HIV‐1 cohort in Bangkok, Thailand and connections within networks of transmission in Asia (2018) (12)
- High Prevalence of Transmitted Drug Resistance in Acute HIV-Infected Thai Men Who Have Sex With Men (2015) (12)
- High-Throughput High-Resolution Class I HLA Genotyping in East Africa (2010) (12)
- SARS-CoV-2 in the U.S. Military — Lessons for Civil Society (2020) (11)
- Helios + Regulatory T cell frequencies are correlated with control of viral replication and recovery of absolute CD4 T cells counts in early HIV-1 infection (2017) (11)
- Relationship between V3 genotype, biologic phenotype, tropism, and coreceptor use for primary isolates of human immunodeficiency virus type 1. (2001) (11)
- Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations (2018) (11)
- HIV-1 Genetic Diversity Among Incident Infections in Mbeya, Tanzania (2016) (11)
- Epidemiology of contemporary seroincident HIV infection in the Navy and Marine corps. (2012) (11)
- Molecular epidemiology of early and acute HIV type 1 infections in the United States Navy and Marine Corps, 2005-2010. (2013) (11)
- A spike-ferritin nanoparticle vaccine induces robust innate immune activity and drives polyfunctional SARS-CoV-2-specific T cells (2021) (11)
- Determinants of suboptimal CD4+ T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV‐1 infection (2020) (10)
- HyperPack: a software package for the study of levels, contexts, and patterns of APOBEC-mediated hypermutation in HIV. (2007) (10)
- Shorter Survival of SDF 1-3 ′ A / 3 ′ A Homozygotes Linked to CD 4 + T Cell Decrease in Advanced Human Immunodeficiency Virus Type 1 Infection (10)
- Herpes simplex virus type 2 and HIV infection among US military personnel: implications for health prevention programmes (2009) (10)
- V3 seroreactivity and sequence variation: tracking the emergence of V3 genotypic variation in HIV-1-infected patients (1996) (10)
- A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells (2011) (10)
- Disclosure of Same-Sex Sexual Practices to Family and Healthcare Providers by Men Who Have Sex with Men and Transgender Women in Nigeria (2020) (10)
- The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination (2021) (10)
- A pilot online survey assessing risk factors for HIV acquisition in the Navy and Marine Corps, 2005-2010. (2012) (10)
- Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. (2016) (9)
- Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test (2019) (9)
- A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model (2022) (9)
- Brief Report: Sexual Risk Behaviors of HIV Seroconverters in the US Army, 2012–2014 (2015) (9)
- Evaluating Vaccination Strategies for Zika Virus in the Americas (2018) (9)
- Short communication: HIV type 1 genetic diversity among tea plantation workers in Kericho, Kenya. (2009) (9)
- Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E (2015) (9)
- Enhanced Sexually Transmitted Infection Screening for Mycoplasma genitalium in Human Immunodeficiency Virus -Infected US Air Force Personnel (2017) (9)
- CD4+ Cell infiltration into subcutaneous adipose tissue is not indicative of productively infected cells during acute SHIV infection (2017) (9)
- Prospecting for an HIV vaccine (2017) (9)
- HIV neutralization assay using polymerase chain reaction-derived molecular signals. (1992) (9)
- An investigation of bloodborne pathogen transmission due to multipatient sharing of insulin pens. (2012) (9)
- A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection (2017) (9)
- IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees (2020) (9)
- RV144 HIV-1 vaccination impacts post-infection antibody responses (2020) (8)
- CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants (2014) (8)
- Next-generation sequencing of HIV-1 single genome amplicons (2019) (8)
- Continuous Prophylactic Antiretrovirals/Antiretroviral Therapy Since Birth Reduces Seeding and Persistence of the Viral Reservoir in Children Vertically Infected With Human Immunodeficiency Virus (2020) (8)
- Expansion of Stem Cell-Like CD4+ Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression (2019) (8)
- Syphilis and Human Immunodeficiency Virus Coinfection: More Than the Sum of Its Parts (2006) (8)
- Review of the U.S. military's human immunodeficiency virus program: a legacy of progress and a future of promise. (2017) (8)
- Brief Report: Safety and Tolerability of Inguinal Lymph Node Biopsy in Individuals With Acute HIV Infection in Thailand (2018) (8)
- Single-Cell Level Response of HIV-Specific and Cytomegalovirus-Specific CD4 T Cells Correlate With Viral Control in Chronic HIV-1 Subtype A Infection (2012) (8)
- HIV status disclosure by Nigerian men who have sex with men and transgender women living with HIV: a cross-sectional analysis at enrollment into an observational cohort (2020) (7)
- Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans (2018) (7)
- Defining epitope coverage requirements for T cell-based HIV vaccines: Theoretical considerations and practical applications (2011) (7)
- The Number and Complexity of Pure and Recombinant HIV-1 Strains Observed within Incident Infections during the HIV and Malaria Cohort Study Conducted in Kericho, Kenya, from 2003 to 2006 (2015) (7)
- A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials. (2021) (7)
- Dendritic cells focus CTL responses toward highly conserved and topologically important HIV epitopes (2020) (7)
- Impact of analytical treatment interruption on the central nervous system in a simian-HIV model. (2019) (7)
- Cross-Sectional Study of Sexual Behavior, Alcohol Use, and Mental Health Conditions Associated With Sexually Transmitted Infections Among Deploying Shipboard US Military Personnel. (2019) (7)
- Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort. (2004) (7)
- New Subtype B Containing HIV-1 Circulating Recombinant of sub-Saharan Africa Origin in Nigerian Men who have Sex with Men. (2019) (7)
- Transmission dynamics among participants initiating antiretroviral therapy upon diagnosis of early acute HIV-1 infection in Thailand (2018) (7)
- B Cell Depletion in HIV-1 Subtype A Infected Ugandan Adults: Relationship to CD4 T Cell Count, Viral Load and Humoral Immune Responses (2011) (7)
- Killer cell immunoglobulin – like receptor 3 DL 1 variation modifies HLA-B * 57 protection against HIV-1 (2018) (7)
- Modeling HIV-1 Latency Using Primary CD4+ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy (2019) (7)
- Central nervous system safety during brief analytic treatment interruption of antiretroviral therapy within four HIV remission trials: an observational study in acutely treated people living with HIV. (2020) (7)
- Biomarkers of Inflammation Correlate With Clinical Scoring Indices in Human Immunodeficiency Virus–Infected Kenyans (2019) (7)
- Demonstration of de novo HIV type 1 production by detection of multiply spliced and unspliced HIV type 1 RNA in paraffin-embedded tonsils. (2002) (7)
- The US Military HIV Natural History Study: Informing Military HIV Care and Policy for Over 30 Years. (2019) (7)
- Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones (2018) (6)
- Phambili: moving forward without the blindfold (2014) (6)
- CTL Clonotypes with Higher TCR Affinity Have Better Ability to Reduce the HIV Latent Reservoir (2020) (6)
- Pre-deployment Alcohol Misuse Among Shipboard Active-Duty U.S. Military Personnel. (2016) (6)
- Centralized HIV Program Oversight: An Investigation of a Case Series of New HIV Infections among US Army Soldiers, 2012 to 2013 (2015) (6)
- Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. (2020) (6)
- Targeted deep sequencing of HIV-1 using the IonTorrentPGM platform. (2014) (6)
- Quantitative analyses reveal distinct sensitivities of the capture of HIV-1 primary viruses and pseudoviruses to broadly neutralizing antibodies. (2017) (6)
- P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA (2009) (6)
- Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIVmac251 Acquisition (2014) (6)
- Improved outlook on HIV-1 prevention and vaccine development (2012) (6)
- Nautilus: a bioinformatics package for the analysis of HIV type 1 targeted deep sequencing data. (2013) (6)
- A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters (2021) (5)
- Sex and Urbanicity Contribute to Variation in Lymphocyte Distribution across Ugandan Populations (2016) (5)
- 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
- Costs and consequences: Hepatitis C seroprevalence in the military and its impact on potential screening strategies (2016) (5)
- IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens (2015) (5)
- Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1 (2021) (5)
- Host genetics and HIV—removing the mask (2002) (5)
- Correlation of tumor suppressor P53 RNA expression with human immunodeficiency virus disease in rapid and slow progressors. (1997) (5)
- Activated PD-1+ CD4 T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART. (2019) (5)
- Differential Loss of Invariant Natural Killer T Cells and FoxP3+ Regulatory T Cells in HIV-1 Subtype A and Subtype D Infections (2013) (5)
- Longitudinal survey of condom use across a US Navy and Marine Corps shipboard deployment (2019) (5)
- Machine Learning Methods Enable Predictive Modeling of Antibody Feature : Function Relationships in RV 144 Vaccinees (2015) (5)
- Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice (2021) (5)
- Assessment of gag DNA and genomic RNA in peripheral blood mononuclear cells in HIV-infected patients receiving intervention with a recombinant gp 160 subunit vaccine in a phase I study. (1994) (5)
- Cautious optimism for HIV vaccine science. (2013) (4)
- Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors (2021) (4)
- Missed opportunity to screen and diagnose PTSD and depression among deploying shipboard US military personnel (2016) (4)
- A high-throughput multiplex assay to characterize flavivirus-specific immunoglobulins. (2020) (4)
- HIV prevalence and risk behavior among male and female adults screened for enrolment into a vaccine preparedness study in Maputo, Mozambique (2019) (4)
- HIV-1 genetic diversity and demographic characteristics in Bulgaria (2019) (4)
- Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques (2021) (4)
- HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019 (2022) (4)
- Characteristics of HIV-infected U.S. Army soldiers linked in molecular transmission clusters, 2001-2012 (2017) (4)
- Two unique recombinant forms identified in incident HIV type 1 infections in Thai blood donors. (2012) (4)
- Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection (2017) (3)
- Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study (2021) (3)
- CD32 does not mark the HIV-1/SIV latent reservoir (2017) (3)
- Neurocognitive impact of Zika virus infection in adult rhesus macaques (2022) (3)
- Efficacy Testing of Recombinant Human Immunodeficiency Virus (HIV) gp160 as a Therapeutic Vaccine in Early-Stage HIV-1–Infected Volunteers (3)
- Factors influencing estimates of HIV-1 infection timing using BEAST (2021) (3)
- Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine (2021) (3)
- Clinical prognosis of patients with early-stage human immunodeficiency virus (HIV) disease: contribution of HIV-1 RNA and T lymphocyte subset quantitation. (2001) (3)
- 3 – Nucleic Acid Blotting Techniques for Virus Detection (1995) (3)
- Standardization of a cytometric p24-capture bead-assay for the detection of main HIV-1 subtypes. (2016) (3)
- Satisfaction with high-resolution anoscopy for anal cancer screening among men who have sex with men: a cross-sectional survey in Abuja, Nigeria (2020) (3)
- Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns (1991) (3)
- An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria (2016) (3)
- Enhanced U.S. Army HIV diagnostic algorithm used to diagnose acute HIV infection in a deployed soldier. (2012) (3)
- Evaluation of HIV-1 neutralizing and binding antibodies in maternal-infant transmission in Thailand. (2020) (2)
- HLA-B∗46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotype. (2022) (2)
- A review of methods for detecting non-reference transposable element insertions from high throughput genome resequencing data. (2013) (2)
- Clinical trial design: The nobility of randomization (2017) (2)
- Chemokine Receptors as HIV-1 Coreceptors (2019) (2)
- Pattern of HIV risk behavior in a cohort of high risk women in East Africa (2012) (2)
- Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques (2022) (2)
- Novel monoclonal antibodies to the SERINC5 HIV-1 restriction factor detect endogenous and virion-associated SERINC5 (2020) (2)
- Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth (2021) (2)
- HIV-1 infections with multiple founders associate with the development of neutralization breadth (2022) (2)
- RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection (2021) (2)
- Boosting with ALVAC-HIV and AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity (2019) (2)
- Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine (2022) (2)
- Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism (2018) (2)
- Simplified steps to heterologous prime-boost HIV vaccine development? (2019) (2)
- Factors associated with testing for HIV and hepatitis C among behaviorally vulnerable men in Germany: a cross-sectional analysis upon enrollment into an observational cohort (2021) (2)
- Hepatitis B seroprevalence in the U.S. military and its impact on potential screening strategies (2020) (2)
- Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand (2015) (1)
- Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells (2022) (1)
- Dissecting drivers of immune activation in chronic HIV-1 infection (2022) (1)
- Cross-Cutting Lessons Learned During the COVID-19 Pandemic—the Walter Reed Army Institute of Research Experience (2021) (1)
- Transfusion—Transmissible Viral Infections among US Military Emergency Transfusion Recipients (2010) (1)
- Abstracts of the 8th HIV Persistence during Therapy Workshop (2017) (1)
- Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants (2022) (1)
- Distinct HIV-Specific Antibody Fc-Profiles in RV144 and VAX003 Vaccinees (2013) (1)
- Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN (2022) (1)
- Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. (2021) (1)
- Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as the primary mechanism of vaccine-induced protection against HIV-1 (2021) (1)
- Correction: RV144 HIV-1 vaccination impacts post-infection antibody responses (2021) (1)
- Delay in viral rebound with TLR7 agonist, N6-LS and PGT121 in SHIV-infected macaques (2019) (1)
- Factors Associated with Not Using a Condom at Last Sex Among Sexually Active US Navy and Marine Corps Personnel Across a Shipboard Deployment (2017) (1)
- A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection (2017) (1)
- Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques (2022) (1)
- Differential viral rebound between lymph node and colon after treatment interruption in SHIV-infected rhesus macaques (2017) (1)
- Aggregate complexes of HIV-1 induced by multimeric antibodies (2014) (1)
- Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines (2022) (1)
- Determining hematological, biochemical and immunological reference values in healthy adults with high-risk for HIV acquisition in Mozambique (2020) (1)
- 167 Magnitude and Breadth of the Neutralizing Antibody Response in RV144 (2011) (1)
- Region of HIV-1 Envelope Preferentially Target Epitopes within the V2 Regimen Induces T Cell Responses That The Thai Phase III Trial (RV144) Vaccine (2012) (1)
- Correction: Trinh, H.V., et al. Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. Cells 2019, 8, 365 (2019) (1)
- Young at risk-people in Maputo City, Mozambique, present a high willingness to participate in HIV trials: Results from an HIV vaccine preparedness cohort study (2021) (1)
- Human T-lymphotropic virus infections in active component service members, U.S. Armed Forces, 2000-2008. (2014) (1)
- Single cell RNA-seq identifies host genes that correlate with HIV-1 reservoir size (2019) (1)
- A Pilot Online Survey Assessing Risk Factors for HIV Acquisition in the Navy and Marine Corps, 2005–2010 (2012) (1)
- HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer (2018) (1)
- Sexual Risk Behaviors of HIV Seroconverters in the U.S. Army, 2012-2014 (2015) (1)
- Major Histocompatibility Complex Genotype Is Associated with Disease Progression and Virus Load Levels in a Cohort of Human Immunodeficiency Virus Type 1–Infected Caucasians and African Americans (1998) (1)
- Preferential and persistent impact of acute HIV-1 infection on CD4+ iNKT cells in colonic mucosa (2021) (1)
- Virion Capture by HIV-1 gp 120-Specific IgG from RV 144 Vaccinees (2013) (1)
- Terminally differentiated CD8 effector T cells have NK-like features and are potent mediators of HIV-specific ADCC (2017) (1)
- Correction: Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial (2016) (1)
- Clinical indicators associated with HIV acquisition in the United States Air Force (2017) (1)
- Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection (2020) (0)
- Alleight unassigned reading frames ofmouse mitochondrial DNA areexpressed (1984) (0)
- Chapter 8 – The design of a global HIV vaccine1 (2012) (0)
- 138 Building on the Results of the RV 144 Prime Boost HIV Vaccine Efficacy Study (2011) (0)
- The CD38+ HLA-DR+ PD-1+ CD4 T cell population represents a short-lived part of the viral reservoir and predicts poor immunologic recovery upon initiation of ART (2017) (0)
- Outcomeof Parameters Affecting Assay Plasma: Immunodeficiency Virus Type 1 RNA in Determinations of Levels of Human (2013) (0)
- Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques (2023) (0)
- PCR amplification, cloning, and construction of HIV-1 infectious molecular clones from virtually full-length HIV-1 genomes. (2005) (0)
- E101 Advances in Preventive HIV Vaccine Development (2013) (0)
- Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate given via standard versus accelerated vaccination schedules: a phase 1, single-center, double-blind, sequential-group, randomized, placebo-controlled clinical trial (2020) (0)
- Erratum: Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells (Science DOI: 10.1126/science.aam8825) (2019) (0)
- Transcriptomic profiles of NK cell function indicate impaired responsiveness in chronic HIV-1 infection and enhanced functional activity post-vaccination (2017) (0)
- Application of W-curves and TSP to Clustering HIV-1 Sequences by Epitope (2010) (0)
- Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine (2019) (0)
- E-102 Advances in Prophylactic HIV Vaccine Development (2014) (0)
- Alcohol Misuse and Associated Risk Factors Across a Shipboard Deployment Among Active Duty US Navy and Marine Corps Personnel (2017) (0)
- Protective effect of an SDF-1 variant in HIV disease: abstract and commentary. (1998) (0)
- Therapeutic vaccination with Ad48/MVA and TLR7 stimulation in SIV-infected, ART-treated infant rhesus macaques (2020) (0)
- Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults (2023) (0)
- Determinants of CD8+ T Cell Immunodominance in Acute HIV-1 Infection (2018) (0)
- Evaluation of Aging and HIV in a Rural Ugandan Cohort: Impact and Challenges (2015) (0)
- Determination of the Promoter Activity of HIV-1 Using the Chloramphenicol Acetyltransferase Reporter Gene Assay. (1999) (0)
- Neurocognitive impact of Zika virus infection in adult rhesus macaques (2022) (0)
- High Numbers Of Activated CD8+ T Cells Targeting HIV Antigens Are Present In Cerebrospinal Fluid In Hyperacute HIV Infection (2017) (0)
- Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy (2018) (0)
- Cellular immunogenicity of an Ad35GGRIN+ENV and MVA-CMDR prime-boost vaccine regimen. (42.3) (2010) (0)
- Galactosylceramide the Interaction of HIV-1 gp 140 with Expose a CD 4-Inducible Epitope and Block Constant Region 1-Specific Antibodies Vaccine-Induced HIV-1 Envelope gp (2014) (0)
- 114 Role of Vaccine-induced V2 Antibodies in Protection From HIV Infection of Recipients in the RV144 Clinical Vaccine Trial (2012) (0)
- 146 Strong and Broad Immunogenicity of a Multigene, Multiclade HIV-1 DNA Prime MVA Boost Vaccine Regimen Among Healthy Tanzanian Volunteers (2011) (0)
- Population-based Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis prevalence using discarded, deidentified urine specimens previously collected for drug testing (2017) (0)
- Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection (2018) (0)
- Cell Type-Specific Proteasomal Processing of HIV-1 Gag-p24 Results in an Altered Epitope Repertoire (cid:1) (2011) (0)
- Referral and access to care of HIV prevalent cases; experience from the early capture HIV cohort study in Kampala (2012) (0)
- Chikungunya in Uganda: Sometimes the Hoof Beats Really Are Zebras (2017) (0)
- HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial (2014) (0)
- Dynamics of Human Immunodeficiency Virus-1 Genetic Diversification During Acute Infection (2020) (0)
- Subtype B Analysis of Subtypes Other than HIV-1 Genotyping Systems in Sequence-Based Immunodeficiency Virus Type 1 ( HIV-1 ) Performance Characteristics of Human (2003) (0)
- Induction of linear and conformational V2-specific antibodies using HIV-1 gp145 clade B envelope protein as the immunogen (P4505) (2013) (0)
- Helios + Regulatory T cell frequencies are correlated with control of viral replication and recovery of absolute CD4 T cells counts in early HIV-1 infection (2017) (0)
- Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Humans is Diminished by Priming with a Yellow Fever or Japanese Encephalitis Virus Vaccine: Elucidating Immunologic Interference between Flavivirus Vaccines (2020) (0)
- Persistent seronegativity and rapid clinical progression in a patient with primary HIV-1 infection (1996) (0)
- Antibody responses induced to the C1 region of HIV-1 gp120 in acute HIV-1 infection and after vaccination (2017) (0)
- Killer cell immunoglobulin – like receptor 3 DL 1 variation modifies HLA-B * 57 protection against HIV-1 Maureen (2018) (0)
- P-A12 Assessing quality of HIV treatment in the United States Military HIV Research Program/Presidentʼs Emergency Plan for AIDS Relief (PEPFAR)-supported programs in Africa (2014) (0)
- F-108 The role of a dual pre- and post- entry innate and adaptive immune mechanism in protection against HIV-1 infection (2016) (0)
- Understanding the determinants of CD8+ T cell immunodominance in acute HIV infection (2017) (0)
- 178 Development of Preventive HIV Vaccines in the US Military HIV Research Program (2009) (0)
- variation differentially regulates influencing HIV disease outcome. (2019) (0)
- Cooling off the host immune response to acute simian immunodeficiency virus infection--is less more? (2013) (0)
- Crystal structure of a human anti-ZIKV-DENV neutralizing antibody MZ1 isolated following ZPIV vaccination (2019) (0)
- Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens (2012) (0)
- 641Acute Retroviral Syndrome is Associated with Gut Mucosal CD4 Depletion, Inflammation and High Viral and Proviral Burden in Systemic and Tissue Compartments (2014) (0)
- Structural Analysis of the Unmutated Ancestor of the HIV-1 Envelope V2 Region Antibody CH58 Isolated From an RV144 HIV-1 Vaccine Efficacy Trial Vaccinee and Associated with Decreased Transmission Risk (2015) (0)
- A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge (2021) (0)
- Large-Scale Human Immunodeficiency Virus Rapid Test Evaluation in a Low-Prevalence Ugandan Blood Bank Population (cid:1) (2007) (0)
- Late Boosting of the RV144 Regimen Improves the Magnitude and Quality of Immune Responses (2019) (0)
- Clinical signs and symptoms associated with acute HIV infection from an intensely monitored cohort on 2 continents (2022) (0)
- SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies (2023) (0)
- Henry M Jackson Foundation for the Advancement of Military Medicine, 1600 East Gude Drive, (2010) (0)
- HIV-1 splice variants and subtype analysis in formalin-fixed, paraffin-embedded tonsils from infected patients (2001) (0)
- Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting (2023) (0)
- 113 Immune Correlates of Infection Risk in the Thai Phase III ALVAC-HIV/AIDSVA-B/E Prime Boost Study (2012) (0)
- Feasibility of high-throughput and low-cost high-resolution class I HLA typing of HIV vaccine trial cohorts in Southeast Asia (2010) (0)
- High-throughput multiplex HLA genotyping by next-generation sequencing using multi-locus individual tagging (2014) (0)
- HIV-1 Infection in Patients with the CCR5-Δ32 Homozygous Genotype (2019) (0)
- Bidirectional transcription of HIV-1 (1994) (0)
- Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies (2023) (0)
- HIV‐1 Infection in Individuals With the CCR5‐&dgr;32/&dgr;32 Genotype: Acquisition of Syncytium‐Inducing Virus at Seroconversion (2002) (0)
- P067 HLA-B*57 Carriage in a post-treatment viral load controller from an hiv-1 therapeutic vaccine clinical trial (2019) (0)
- Author response: Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1 (2021) (0)
- Molecular Evolution of the HIV-1 Thai Epidemic between the Time of RV144 Immunogen Selection to the Execution of the Vaccine Efficacy Trial (2013) (0)
- A novel acute HIV infection staging system based on 4thgeneration immunoassay (2013) (0)
- Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques (2022) (0)
- This information is current as and AIM 2 Sensor Type I IFN Pathway − STING − cGAS / IFI 16 Canarypox Virus Vector ALVAC via the Priming and Activation of Inflammasome by Sun (2017) (0)
- Crystal structure of a human anti-ZIKV-DENV neutralizing antibody MZ4 in complex with ZIKV E glycoprotein (2019) (0)
- Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination (2018) (0)
- New Challenges and Opportunities for HIV Vaccines and Insights from Studies of Acute HIV Infection (2015) (0)
- CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome (2019) (0)
- PROSPECTIVE AND RETROSPECTIVE TESTING OF HIGH PREVALENCE HIV-1 SERUM AND BLOOD USING RAPID AND CONVENTIONAL TECHNOLOGY (2006) (0)
- Crystal structure of a human anti-ZIKV-DENV neutralizing antibody MZ1 in complex with ZIKV E glycoprotein (2019) (0)
- Gag-Specific Cellular Immunity Determines In Vitro Viral Inhibition and In 2 (2012) (0)
- Crystal structure of unliganded CH59UA, the inferred unmutated ancestor of the RV144 anti-HIV antibody lineage producing CH59 (2015) (0)
- CCR 2-64 I Polymorphism , Syncytium-Inducing Human Immunodeficiency Virus Strains , and Disease Progression (2010) (0)
- B-105 Studies of Acute HIV Infection –Insights for Cure (2014) (0)
- Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor (2020) (0)
- O09.7 Knowledge, attitudes, and beliefs about hiv pre-exposure prophylaxis among u.s. army health care providers (2017) (0)
- Viral Isolates with Length Polymorphisms Immunodeficiency Virus Type 1 Clades and Drug Resistance Genotyping of Human HIV PRT 440 Platform for Antiretroviral Performance of the Affymetrix GeneChip (1999) (0)
- SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses (2021) (0)
- Material for Adjuvant dependent innate and adaptive immune signatures of risk of SIVmac 251 acquisition (2016) (0)
- Correction: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition (2016) (0)
- OR23 HLA class II genes correlate with protective neutralizing antibody titers in a dengue vaccine efficacy trial (2018) (0)
- Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant (2017) (0)
This paper list is powered by the following services:
Other Resources About Nelson Michael
What Schools Are Affiliated With Nelson Michael?
Nelson Michael is affiliated with the following schools:
